Dr Reddy’s Laboratories is preparing to introduce its generic semaglutide injection in India, likely to be marketed under the brand name Obeda, following the expiry of the molecule’s patent protection in March 2026, according to industry sources.

Semaglutide, a GLP-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity, is currently marketed globally by Novo Nordisk under brands such as Ozempic and Wegovy. The upcoming patent expiry is paving the way for Indian pharmaceutical companies to enter the segment with locally manufactured alternatives.

Sources suggest Dr Reddy’s plans to launch the therapy in injectable pen format and scale production during the initial rollout phase. The company has already received approval to manufacture and market a generic equivalent of Ozempic in India and is awaiting regulatory clearance related to the obesity indication.

Industry stakeholders expect increased activity in the GLP-1 segment as multiple domestic drugmakers prepare launches post-patent expiry, signalling heightened competition in the injectable antidiabetic and anti-obesity therapy market.

The company has not officially confirmed the launch timeline or branding, though trademark filings linked to the name Obeda have been reported.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!